Clinical Trials Logo

Recurrent Inflammatory Breast Carcinoma clinical trials

View clinical trials related to Recurrent Inflammatory Breast Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT02892734 Recruiting - Clinical trials for Stage IV Breast Cancer

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

Start date: September 5, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to look at the efficacy (the effect on tumor) and the safety (the effect on body) of the study drugs when given as a combination in patients with metastatic recurrent epidermal growth factor receptor 2 (HER2) negative inflammatory breast cancer. This is a phase II study of 2 drugs used in combination: nivolumab and ipilimumab. The combination of these drugs is already approved by the Food and Drug Administration (FDA) to treat advanced melanoma (a type of skin cancer). Nivolumab and ipilimumab are not approved by the FDA for patients with metastatic recurrent HER2 negative inflammatory breast cancer, hence the treatment is considered experimental or investigational.